A comparative study of efficacy and safety of topical travoprost 0.004% versus latanoprost 0.005% in the treatment of primary open angle glaucoma at a tertiary care hospital
Journal Title: International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP) - Year 2017, Vol 6, Issue 2
Abstract
Introduction Glaucoma, “silent thief of sight” is a chronic, progressive optic neuropathy leading to optic nerve damage and visual field loss. Lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) is beneficial in reducing the risk for visual field loss in the long term. Various prostaglandin analogues have demonstrated consistent superiority over other therapies in terms of IOP reduction, however superiority amongst them remains inconclusive. Objectives To compare efficacy and safety of topical travoprost 0.004% versus latanoprost 0.005% in reducing intraocular pressure in patients with POAG. Materials and methods 60 newly diagnosed patients of POAG who fulfilled the inclusion /exclusion criteria were randomised into two groups of 30 each to receive either travoprost or latanoprost once daily in the evening. Efficacy was measured in terms of reduction in IOP monitored at 4, 8 and 12 weeks from baseline. Safety was assessed by monitoring treatment emergent adverse drug reactions. Results Both travoprost and latanoprost effectively reduced IOP when compared to baseline. Mean IOP reduction from baseline to week 12 was 9.08 ± 1.93 mmHg (p<0.001), 7.96 ± 1.11 mmHg, (p<0.001) in travoprost and latanoprost groups respectively. There was significant reduction in IOP with travoprost when compared to latanoprost (8.86 ± 2.07 vs 7.71 ± 0.92, p=0.0003) at the end of 8 weeks and the same trend continued even at 12 weeks (9.08 ± 1.93 mmHg vs 7.96 ± 1.11 mmHg, p< 0.0002). Adverse drug reactions (ADR) were comparable in both the groups with conjunctival hyperaemia (21.6%) being the most common ADR. Conclusion Travoprost was found to be more efficacious in reducing IOP as early as 8 weeks as compared to latanoprost. There was an additional 1.12 mmHg reduction in IOP at the end of 12 weeks in comparison to latanoprost and it was well tolerated. Hence travoprost could be a favourable option for the treatment of primary open angle glaucoma.
Authors and Affiliations
C R Jayanthi
Keywords
Related Articles
- EP ID EP412930
- DOI -
- Views 134
- Downloads 0
Niosomes: An excellent tool for drug delivery
The ideal drug delivery system delivers drug at rate dictated by the need of the body over the period of treatment and it channels the active entity solely to the site of action. Niosomes are non-ionic surfactant vesicl...
Studying the effects of Ruta graveolens on spontaneous motor activity, skeletal muscle tone and strychnine induced convulsions in albino mice and rats
Ruta graveolens is a plant commonly found in north Africa and south Europe. It is reported that Ruta graveolens is used traditionally for epilepsy and some other illnesses. The acute and sub-acute effects of alcoholic e...
Medication Adherence Pattern Of Hypertensive Patients In Rural Area
AIM & OBJECTIVES The study investigated the level of drug adherence among hypertensive patients at a tertiary care hospital in Erode, Tamil Nadu. Specific objectives included measurement of blood pressure (BP) control a...
Prediction of target enzyme for diabetes mellitus by isolated blood samples
Diabetes Mellitus is a serious problem universally, by and large in both developing as well as underdeveloped nations. Conversely, a synthetic drug management of diabetes mellitus creates an unexpected adverse effect tow...
Triphala an innovative medicine of the centuries
TRIPHALA had been described from the Era of Charak and Sushruta as a medicine with multiple properties. The drug Triphala is a combination of fruits of Terminalia chebula Retz, Terminalia bellirica Roxb and Emblica offic...